The National Authority of Medicines (Infarmed) has announced the recall of specific batches of the drug Duloxetina Bluepharma. This decision follows the detection of an analytical result that exceeded acceptable impurity limits.
The recall affects batches of Duloxetina Bluepharma gastro-resistant capsules in 30mg and 60mg dosages, produced by Bluepharma Genéricos – Comércio de Medicamentos S.A. An informative circular was shared on Infarmed’s website detailing these issues.
Entities holding stock of the affected batches are instructed not to sell, dispense, or administer them and are required to proceed with their return.
Patients using medications from these batches are advised not to discontinue treatment abruptly. They should consult their doctor as soon as possible to assess the need for substitution with an alternative medication.
What is Duloxetina Bluepharma?
According to the site Índice, Duloxetina primarily targets major depressive disorder, generalized anxiety disorder, and pain associated with diabetic peripheral neuropathy.
